



CADTH Reimbursement Review

Provisional Funding Algorithm

Indication: Large B-cell lymphoma

This report supersedes the CADTH Provisional Funding Algorithm report for large B-cell lymphoma dated April 2024.

Please always check [CADTH Provisional Funding Algorithms | CADTH](#) to ensure you are reading the most recent algorithm report.

August 2024

Background

Following a request from jurisdictions, CADTH may design or update an algorithm depicting the sequence of funded treatments for a particular tumour type. These algorithms are proposals for the jurisdictions to implement and adapt to the local context. As such, they are termed “provisional.” Publishing of provisional algorithms is meant to improve transparency of the oncology drug funding process and promote consistency across jurisdictions.

Provisional funding algorithms are based on 3 principal sources of information:

- pan-Canadian Oncology Drug Review Expert Review Committee (pERC) Reimbursement Recommendations and/or implementation guidance regarding drug place in therapy and sequencing
- implementation advice from panels of clinicians convened by CADTH concerning sequencing of drugs in the therapeutic space of interest
- existing oncology drug reimbursement criteria and legacy funding algorithms adopted by jurisdictional drug plans and cancer agencies.

Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management of each patient nor the provision of each drug regimen. The diagrams may not contain a comprehensive list of all available treatments, and some drugs may not be funded in certain jurisdictions. All drugs are subject to explicit funding criteria, which may also vary between jurisdictions. Readers are invited to refer to the cited sources of information on the CADTH website for more details.

Provisional funding algorithms also delineate treatment sequences available to patients who were never treated for the condition of interest (i.e., incident population). Time-limited funding of new options for previously or currently treated patients (i.e., the prevalent population) is not detailed in the algorithm.

Provisional funding algorithms may contain drugs that are under consideration for funding. Algorithms will not be dynamically updated by CADTH following changes to drug funding status. Revisions and updates will occur only upon request by jurisdictions.

Jurisdictional cancer drug programs requested a CADTH provisional funding algorithm on large B-cell lymphoma (LBCL). However, no outstanding implementation issues were identified, and no additional implementation advice is provided in this report. The algorithm depicted herein is meant to reflect the current and anticipated funding landscape based on the previously mentioned sources of information.

History and Development of the Provisional Funding Algorithm

CADTH published the first rapid provisional algorithm for LBCL in April 2023 to incorporate CADTH recommendations for axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and polatuzumab vedotin (Polivy).

In addition, the April 2023 algorithm for LBCL also incorporated the relevant Health Technology Expert Review Panel (HTERP) recommendations for tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta).

In April 2024, the provisional algorithm for LBCL was updated to incorporate the CADTH recommendation for glofitamab (Columvi).

Jurisdictional cancer drug programs requested an update to this rapid algorithm report in May 2024 to incorporate the CADTH recommendation for epcoritamab (Epkincy).

Details of the relevant CADTH recommendations are outlined in [Table 1](#).

Table 1: Relevant CADTH or HTERP Recommendations

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
Epcoritamab (Epkincy)	June 18, 2024	<p>pERC recommends that epcoritamab be reimbursed for the treatment of adults with r/r DLBCL not otherwise specified, DLBCL transformed from indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma grade 3B after 2 or more lines of systemic therapy and who have previously received or are unable to receive CAR T-cell therapy for a time-limited period while additional evidence is generated and only if the following conditions are met:</p> <p>Initiation:</p> <ol style="list-style-type: none"> 1. Adults (≥ 18 years) with both of the following: <ol style="list-style-type: none"> 1.1. relapsed or refractory DLBCL not otherwise specified, DLBCL transformed from indolent lymphoma, HGBCL, PMBCL, or FLG3b 1.2. have received 2 or more lines of systemic therapy and have previously received CAR T-cell therapy; or have declined, are ineligible to receive, or cannot receive CAR T-cell therapy. <p>Discontinuation:</p> <ol style="list-style-type: none"> 2. Treatment with epcoritamab should be discontinued upon the occurrence of any of the following: <ol style="list-style-type: none"> 2.1. objective disease progression 2.2. unacceptable toxicity 3. Patients should be initially assessed clinically at least every 3 months until disease progression, with imaging based on local standards. <p>Prescribing:</p> <ol style="list-style-type: none"> 4. Epcoritamab should be prescribed by clinicians (hematologists or oncologists) with expertise in the management of LBCL. 5. Epcoritamab should not be reimbursed when given in combination with other systemic anticancer drugs. <p>Pricing:</p> <ol style="list-style-type: none"> 6. A reduction in price. <p>Feasibility of adoption:</p> <ol style="list-style-type: none"> 7. The organizational feasibility must be addressed so that jurisdictions have the infrastructure in place to implement treatment with epcoritamab: <ol style="list-style-type: none"> 7.1. access to specialized inpatient facilities for monitoring patients after the full dose of epcoritamab.

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>Time-limited reimbursement:</p> <p>8. This recommendation in favour of reimbursement is time-limited and contingent on a future reassessment of additional evidence that addresses the uncertainty.</p> <p>(Please note that time-limited reimbursement refers to temporary reimbursement by the drug programs while additional evidence is generated and submitted for reassessment [i.e., this does not refer to the length of treatment or number of cycles administered]).</p> <p>Guidance on sequencing:</p> <ul style="list-style-type: none"> The clinical experts consulted by CADTH noted that eligibility for CAR T-cell therapy is determined by patient factors (e.g., age, cardiac function, renal function, liver function), tumour factors (e.g., rate of tumour progression; extent of extranodal involvement), and issues related to CAR T-cell manufacturer and health system capacity. <p>However, pERC noted that there is no evidence to support CAR T-cell therapy after epcoritamab.</p> <ul style="list-style-type: none"> The clinical experts and pERC agreed that CAR T-cell therapy would generally be the preferred option for patients who are sufficiently fit to receive the treatment given that it can be curative regimen and there is longer-term follow-up data in comparison with bispecific therapies, such as epcoritamab. <p>The clinical experts and pERC also noted that treatment with CAR T-cell therapy is resource-intensive and this can lead to equity and access issues depending on health care system considerations. Additional treatment options, such as epcoritamab, are required for patients who are not candidates for CAR T-cell therapy.</p> <ul style="list-style-type: none"> The clinical experts consulted by CADTH do not believe there is a clinical rationale for why patients should be required to have prior CAR T-cell therapy or be unable to receive CAR T-cell therapy to be eligible for epcoritamab. The clinical experts noted that epcoritamab has been shown to be clinically beneficial for patients who could be considered candidates for CAR T-cell therapy. <p>Acknowledging the absence of studies directly comparing epcoritamab against CAR T-cell therapies, the clinical experts consulted by CADTH noted that CAR T-cell therapy would generally be the preferred option for patients who are sufficiently fit to receive the treatment given that it can be curative regimen and there is longer-term follow-up data.</p>
Glofitamab (Columvi)	February 21, 2024	<p>pERC recommends that glofitamab be reimbursed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR T-cell therapy or have previously received CAR T-cell therapy only if the following conditions are met:</p> <p>Initiation:</p> <ol style="list-style-type: none"> Adult (≥ 18 years) patients with both of the following:

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>1.1. relapsed or refractory DLBCL not otherwise specified, trFL, or PMBCL</p> <p>1.2. have received 2 or more lines of systemic therapy and have previously received CAR T-cell therapy; declined, are ineligible to receive, or cannot receive CAR T-cell therapy.</p> <p>Discontinuation:</p> <p>2. Treatment with glofitamab should be discontinued upon the occurrence of any of the following:</p> <p>2.1. objective disease progression or a maximum of 12 cycles</p> <p>2.2. unacceptable toxicity.</p> <p>3. Patients should be initially assessed clinically at least every 3 months until disease progression or fixed treatment duration of 12 cycles, with imaging based on local standards.</p> <p>Prescribing:</p> <p>4. Glofitamab should be prescribed by clinicians (hematologists or oncologists) with expertise in the management of DLBCL.</p> <p>5. Glofitamab should not be reimbursed when combined with other systemic anticancer drugs.</p> <p>Pricing:</p> <p>6. A reduction in price.</p> <p>Feasibility of adoption:</p> <p>7. The feasibility of adoption of glofitamab must be addressed.</p> <p>Guidance on sequencing:</p> <ul style="list-style-type: none"> • The clinical experts and pERC agreed that the only currently available publicly funded comparator includes pola-BR. CAR T-cell therapy is not considered a relevant comparator to glofitamab, as in the treatment sequence, if patients were eligible for CAR T-cell therapy, they would receive it before glofitamab. For patients who are ineligible for CAR T-cell therapy, or decline or cannot access CAR T-cell therapy, glofitamab may be given. • pERC noted that patients who were not previously treated with an anthracycline-containing regimen (e.g., indolent disease, contraindication), should still be eligible for treatment with glofitamab. • Regarding prior allogeneic SCT, the clinical experts highlighted that certain caveats including the absence of GVHD or no longer taking immunosuppressive therapies would be required to use glofitamab in these patients, however, no evidence exists. • In the NP30179 study, patients were eligible for re-treatment with glofitamab provided they met all eligibility criteria, and initially had a radiographically documented, investigator-assessed objective response (CR or PR) or SD at the end of the full initial glofitamab treatment regimen. No time frame for relapse was specified. <p>The clinical experts and pERC indicated that re-treatment with glofitamab could be considered in alignment with the clinical trial protocol (i.e., if patients experienced a good outcome following the initial treatment with glofitamab, re-treatment would be given for a</p>

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>maximum of 12 cycles or until progression, whichever occurs first). pERC noted there was insufficient evidence to define a sufficient durable response that would be reasonable before re-treatment was considered; however, based on clinical experience, a durable response for at least 6 months in a patient who had not progressed on therapy may be considered reasonable.</p> <ul style="list-style-type: none"> The clinical experts agreed that the requirement for performance status in determining treatment eligibility is less stringent in clinical practice and select patients with an ECOG performance status of 2 could be considered for treatment with glotitamb.
Axicabtagene ciloleucel (Yescarta)	February 22, 2023	<p>pERC recommends that axicabtagene ciloleucel (axi-cel) be reimbursed for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, who are eligible for autologous stem cell transplant (ASCT) only if the following conditions are met:</p> <p>Initiation:</p> <ol style="list-style-type: none"> Axi-cel should be reimbursed in adult patients with DLBCL or HGBL only if all of the following criteria are met: <ol style="list-style-type: none"> refractory to first-line chemoimmunotherapy or relapsed within 12 months of first-line chemoimmunotherapy. eligible for ASCT. have a good performance status. Axi-cel should not be reimbursed for patients who have had previous CAR T-cell therapy. <p>Renewal:</p> <ol style="list-style-type: none"> Treatment with axi-cel is a 1-time therapy. <p>Prescribing:</p> <ol style="list-style-type: none"> Axi-cel should be prescribed by clinicians with expertise in the management of lymphomas and CAR T-cell toxicities. Axi-cel should be administered in a hospital setting with adequate infrastructure, resources, and expertise to perform the procedure and manage side effects. <p>Pricing:</p> <ol style="list-style-type: none"> A reduction in price. <p>Feasibility of adoption:</p> <ol style="list-style-type: none"> The feasibility of adoption of axi-cel must be addressed. <p>Guidance on sequencing:</p> <ul style="list-style-type: none"> With regard to DLBCL arising from FL, pERC agreed with the clinical experts, who indicated that in clinical settings, the diagnosis of transformation may be clinically driven, based on patient symptoms and signs, rather than pathologically driven. In some cases, biopsy is unavailable or risky to obtain. Therefore, a high clinical suspicion of transformation is sufficient and biopsy-proven DLBCL is not necessary to confirm transformation to DLBCL. <p>The clinical experts indicated that, generally, once the diagnosis of</p>

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>transformation is made, line of therapy for the transformation (i.e., CAR T-eligible disease) starts at that point. However, the clinical experts noted that if a patient FL has already been given therapy that is an active regimen for high-grade lymphoma including DLBCL that includes a rituximab-containing regimen with anthracycline (e.g., R-CHOP), especially when treatment is recent, the patients should be regarded as having failed first-line therapy and should be eligible for second-line CAR T-cell therapy.</p> <p>To be considered for second-line CAR T-cell therapy, the clinical experts noted that patients should have been exposed to a rituximab-containing regimen with an anthracycline as in the ZUMA-7 trial (or etoposide if an anthracycline was unavailable) whether for DLBCL or FL transformed into LBCL.</p> <ul style="list-style-type: none"> • The clinical experts clarified that the definition of relapsed disease used in the ZUMA-7 trial is reasonable and indicated this definition could be applied to eligibility criteria for axi-cel (i.e., relapse, within 12 months from date of last exposure to active therapy). pERC noted that this is specified in the Health Canada indication. • pERC agreed with the clinical experts, who indicated patients with ECOG ≤ 2 can be considered for CAR T-cell therapy. • pERC noted that there is no evidence to support using of axi-cel in patients who received prior CD-19-targeted therapy. • pERC noted that patients with a history of a Richter's transformation of chronic lymphocytic leukemia are managed differently than with patients with LBCL. The clinical experts indicated that patients with PMBCL should be eligible for CAR T-cell therapy. • pERC noted that there is currently no evidence to support CAR T-cell re-treatment in patients who had received a prior CAR T-cell therapy. • pERC agreed with the clinical experts, who indicated that as long as the CNS disease is treated and the patient is neurologically stable, they should be eligible for CAR T-cell therapy. • pERC agreed with the clinical experts, who indicated that bridging therapies other than corticosteroids can be used. Any standard salvage chemotherapy regimen (e.g., R-GemOx, R-GDP, R-ICE, R-DHAP, R-ESHAP, pola-BR) could be used as bridging therapy. • The clinical experts indicated that depending on where the patient is in the course of treatment (e.g., completed salvage chemotherapy and a plan is in place for transplant), they should be allowed to switch to CAR T-cell therapy. pERC agreed that the decision to have CAR T-cell therapy rather than ASCT would be at the discretion of the treating hematologist in discussion with the patient. • pERC agreed with the clinical experts, who reported that other treatments may be used to manage cytokine release syndrome (CRS). These include siltuximab, a next-generation IL-6 inhibitor, and steroids if an IL-6 inhibitor is unavailable.

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
Tafasitamab (Minjuvi)	October 13, 2022	pERC recommends that tafasitamab not be reimbursed in combination with lenalidomide for the treatment of adult patients with R/R DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for ASCT.
Lisocabtagene maraleucel (Breyanzi)	July 18, 2022	<p>pERC recommends that lisocabtagene maraleucel (liso-cel) be reimbursed for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, only if the following conditions are met:</p> <p>Initiation:</p> <ol style="list-style-type: none"> 1. Liso-cel should be reimbursed in adult patients with relapsed or refractory LBCL according to the following criteria: <ol style="list-style-type: none"> 1.1. DLBCL not otherwise specified, HGBCL, PMBCL, DLBCL arising from follicular lymphoma AND 1.2. relapsed or refractory to at least 2 prior lines of systemic therapy including a CD20-targeted agent. 2. Patients must have a good performance status. 3. Liso-cel should not be reimbursed for patients who have had a previous CAR T-cell therapy. 4. Liso-cel should be reimbursed in patients with secondary CNS involvement as long as they fulfill all other criteria. <p>Renewal:</p> <ol style="list-style-type: none"> 5. Treatment with liso-cel is a 1-time therapy. <p>Prescribing:</p> <ol style="list-style-type: none"> 6. Liso-cel should be prescribed by clinicians with expertise in the management of lymphomas and CAR T-cell toxicities. It should be administered at manufacturer-certified transplant centres with the necessary resources and human expertise to perform the procedure and manage side effects. <p>Pricing:</p> <ol style="list-style-type: none"> 7. Liso-cel should be negotiated so that it does not exceed the drug program cost of treatment with the least costly CAR T-cell therapy reimbursed for the treatment of relapsed or refractory LBCL. <p>Feasibility of adoption:</p> <ol style="list-style-type: none"> 8. The feasibility of adoption of liso-cel must be addressed. <p>Guidance on sequencing:</p> <ul style="list-style-type: none"> • pERC noted that PET results are not required before lymphodepleting therapy or cell infusion because PET results are expected to be positive in most patients whether or not bridging therapy is used. • pERC noted that patients would need at least 2 lines of systemic therapy from the time of diagnosis of the transformed DLBCL. Potential exception may include individuals with follicular lymphoma for which they already have received induction chemotherapy followed by ASCT, but then transformed to DLBCL/HGBCL. For

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>these cases, clinicians may want to move directly to offer CAR T-cell therapies because other options are limited. Clinical experts suggest criteria could stipulate the minimum types of therapy required in these situations.</p> <ul style="list-style-type: none"> • Eligibility criteria for liso-cel would overlap with axi-cel and tisa-cel. The approved indication aligns with the axi-cel indication and does not include DLBCL from indolent lymphomas and follicular lymphoma grade 3B; therefore, pERC cannot provide guidance on these populations. • pERC and clinical experts indicated that liso-cel would be considered for use in patients who are > 75 years old, have ECOG PS > 2, or have CNS involvement. pERC and clinical experts emphasized the need for more data, especially comparative data. TRANSCEND is the first study to include the patients with CNS involvement and prior allo-SCT. pERC and clinical experts noted that both of these subgroups of patients represent a small proportion of the population in practice, making it difficult for studies to be conducted with these subgroups specifically. • Patients with comorbidities are eligible, but patients require sufficient cardiac function to survive CRS or sepsis, and renal function to tolerate fludarabine. Currently, there is variability on the approach to patients with comorbidities by Canadian centres. • There are currently no data to support that patients who have received previous CAR T-cell therapies for DLBCL should receive liso-cel. Responses to a second (different) CAR T-cell product is unknown and should be studied independently. • A small proportion of patients in TRANSCEND were re-challenged with liso-cel. According to the clinical experts and pERC, there remains insufficient data on the outcome of such a scenario to support re-treatment. • pERC and the experts agreed that patient with secondary CNS involvement can be eligible as per the clinical trial eligibility criteria. This population is in great need of better therapies. • According to experts and pERC, it is not expected that liso-cel would be better than other CAR T-cell therapies, but it may be offered to a broader population of patients with CNS disease. <p>Although there is a perception of a better safety profile, experts agreed that it may be a result of clinicians having a better understanding on how to better manage CRS and ICANS, which would lead to more favourable outcomes, although the evidence is still uncertain to support any assumption.</p> <p>Another expert mentioned that there is no clear clinical evidence to favour 1 CAR T-cell therapy over another for the overlapping indications. However, in practice, some centres may choose to align with a limited number of manufacturers to minimize contractual and manufacturer-specific requirements (i.e., it is possible 1 will be favoured for logistical reasons).</p> <ul style="list-style-type: none"> • pERC and clinical experts agree that liso-cel may have a better

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>safety profile, but there is still uncertainty around this issue. For now, it would be important to focus on the proportion treated as outpatients in the TRANSCEND study.</p> <p>The use of tocilizumab and possible drug shortages is a concern because the companies require 2 doses on hand for each patient. The use of siltuximab has been considered by some clinicians if there is a severe shortage. A biosimilar tocilizumab would be helpful in the future.</p>
<p>Polatuzumab vedotin (Polivy)</p>	<p>April 21, 2021</p>	<p>pERC conditionally recommends the reimbursement of polatuzumab vedotin in combination with bendamustine and rituximab (pola-BR) for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who are not eligible for autologous stem cell transplant (ASCT), if the following conditions are met:</p> <ul style="list-style-type: none"> • cost-effectiveness is improved to an acceptable level • feasibility of adoption (budget impact) is addressed. <p>Eligible patients should have good performance status (PS) and a life expectancy greater than or equal to 24 weeks. Patients must have received at least 1 prior therapy. Treatment with pola-BR should continue for a maximum of 6 cycles (21 days per cycle) or until unacceptable toxicity or disease progression, whichever comes first.</p> <p>Guidance on sequencing:</p> <p>Based on the GO29365 trial eligibility criteria, pERC agreed with the CGP on the eligibility of the following groups of patients:</p> <ul style="list-style-type: none"> • Pediatric patients: Pediatric patients were not included in the trial, and thus would not be eligible for pola-BR. • Prior ASCT: Patients with prior ASCT were eligible for the GO29365 trial, and thus would be eligible for pola-BR. • Progression on CAR T-cell therapy: Patients with prior CAR T-cell therapy were eligible for the trial, and thus would be eligible for pola-BR. • Failed vs. ineligible for ASCT: Per the inclusion criteria, patient who were ineligible for or failed ASCT were eligible for the trial, and thus would be eligible for treatment with pola-BR <p>pERC agreed with the CGP on the following sequencing scenarios:</p> <ul style="list-style-type: none"> • Options after failure on pola-BR: Treatment options after progression on pola-BR should be up to the treating clinician; however, options such as anti-CD19 or CAR T-cell therapies could be considered. • Use of pola-BR as a bridge to CAR T-cell therapy and omitting bendamustine: Bendamustine can be omitted if appropriate based on clinical judgment. However, there is no evidence to support its use in this way. • Number and types of prior therapies: Consistent with the GO29365 trial, patients who were R/R after at least 1 prior line of therapy and were transplant-ineligible would be eligible for pola-BR. • Switching to polatuzumab vedotin plus other chemo-immunotherapies if BR is not tolerated: As previously noted, there

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>is no evidence to support the safe use of polatuzumab vedotin in combination with other chemo-immunotherapies.</p>
<p>Axicabtagene ciloleucel (Yescarta)</p>	<p>August 2019</p>	<p>On the condition that there is a substantial reduction in price, HTERP recommends the provision of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Regarding implementation of this therapy, HTERP recommends:</p> <ul style="list-style-type: none"> the creation of interprovincial agreements to ensure equitable access to eligible patients in all jurisdictions, including consideration of financial and logistic support for required travel and short-term relocation the development of clear and transparent eligibility criteria that are acceptable to patients' and clinicians' needs, based on the approved indications the collection of standardized outcomes data in a pan-Canadian registry of patients, which uses a defined set of outcomes and definitions to generate additional real-world evidence, for consideration in future reassessments of longer-term effectiveness, safety, and cost-effectiveness. <p>Implementation analysis:</p> <p>The implementation analysis was guided by 2 research objectives:</p> <ul style="list-style-type: none"> Provide a detailed description of potential pathways of care for patients to receive axicabtagene ciloleucel, and the resources (e.g., health and human resources, training, organizational) needed to do so. Provide an overview of feasibility and capacity considerations relating to the provision of axicabtagene ciloleucel at the level of the individual patient and provider (i.e., micro level); hospital or health care organization such as health authority or region (i.e., meso level); and the provincial, territorial, and federal levels (i.e., macro level). <p>Structuring the provision of axicabtagene ciloleucel raises several challenges. The management of toxicities and potential for severe AEs, coupled with the need for ongoing data collection help shape potential models of delivery. The proposed model of delivery is that axicabtagene ciloleucel be delivered at manufacturer-trained and qualified hematopoietic stem cell transplantation sites. The process for onboarding of sites across Canadian jurisdictions may take time, and supporting treatment across and within jurisdictions through reimbursement mechanisms and resources for patient travel (financial and logistical) may mitigate potential geographic inequalities.</p> <p>As treatment sites grapple with several levels of oversight and gaining accreditation for multiple products, deciding which organizations are most suited to provide treatment sites' oversight, as well as the roles of the Foundation for the Accreditation of Cellular Therapies accreditation and of the manufacturer, involves complex</p>


Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>considerations.</p> <p>Patient selection will likely involve the selection of patients who are less stable than those in the pivotal trial supporting regulatory approval of axicabtagene ciloleucel, and bridging therapy will also likely be used in practice. Patient selection may occur across the process of receiving the therapy, and processes for allocating manufacturing slots as they become available will be needed. Uncertainty around long-term clinical effectiveness, cost-effectiveness, and safety raises challenges for regulatory agencies and payers when making decisions, highlighting the need for long-term data collection.</p>
Tisagenlecleucel (Kymriah)	January 2019	<p>On the condition that there is a substantial reduction in price, HTERP recommends the provision of tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. With regard to implementation of this therapy, HTERP recommends:</p> <ul style="list-style-type: none"> • the creation of interprovincial agreements to ensure equitable access to eligible patients in all jurisdictions, including consideration of financial and logistic support for required travel and short-term relocation • the development of clear and transparent eligibility criteria that are acceptable to patients' and clinicians' needs, based on the approved indications • the collection of standardized outcomes data in a pan-Canadian registry of patients, which uses a defined set of outcomes and definitions to generate real-world evidence, for consideration in future reassessments to assess longer-term effectiveness, safety, and cost-effectiveness. <p>Implementation analysis:</p> <p>The implementation analysis had the following objectives:</p> <ul style="list-style-type: none"> • to provide a detailed description of potential pathways of care for patients to receive tisagenlecleucel, and the resources (e.g., health and human resources, training, organizational) needed to do so; and, • to provide an overview of feasibility and capacity considerations relating to the provision of tisagenlecleucel at the level of the individual patient and provider (i.e., micro level); via hospital or health care organizations such as regional health authorities (i.e., meso level); and at the provincial, territorial, and federal levels (i.e., macro level). <p>The analysis described the proposed model of access within Canada and across jurisdictions. A centralized model of access with manufacturer-trained sites is required by the FDA and the European Medicines Agency to address key safety concerns about the management of potential AEs. Many stakeholders see accreditation by FACT as ensuring the necessary resources, experience, policies, and procedures to safely deliver CAR T-cell therapy and collect long-term data.</p>

Generic name (brand name)	Date of recommendation	Recommendation and guidance on treatment sequencing
		<p>The ability to deliver effectiveness therapy is dependent on timely access and provision. However, providing tisagenlecleucel may exacerbate existing capacity issues (such as treatment and clinical resources, space, and workforce) related to provision of hematopoietic SCT. Within Canada, a centralized model may create geographic inequities. Travel and relocation to receive treatment has economic, social, physical, and psychological impacts for patients and carers. Similar to other therapies delivered using a centralized model, consideration should be given to support services for patients, carers, and families, including travel support, lodging, and psychosocial support.</p> <p>The analysis also found that developing and applying eligibility criteria is a key implementation challenge. Clear and transparent eligibility criteria that are based on approved indications and that are acceptable to clinicians and patients are needed. Interprovincial agreements on the appropriate eligibility criteria will be required to ensure equitable access.</p>

AE = adverse event; ASCT = autologous stem cell transplant; axi-cel = axicabtagene ciloleucel; CAR = chimeric antigen receptor; CGP = Clinical Guidance Panel; CNS = central nervous system; CR = complete response; CRS = cytokine release syndrome; DLBCL = diffuse large B-cell lymphoma; ECOG = Eastern Cooperative Oncology Group; FL = follicular lymphoma; GVHD = graft-versus-host disease; HGBCL = high-grade B-cell lymphoma; HTERP = Health Technology Expert Review Panel; LBCL = large B-cell lymphoma; liso-cel = lisocabtagene maraleucel; pERC = pan-Canadian Oncology Drug Review Expert Review Committee; PMBCL = primary mediastinal large B-cell lymphoma; pola-BR = polatuzumab vedotin in combination with bendamustine and rituximab; PR = partial response; R-CHOP = rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DHAP = rituximab, dexamethasone, cytarabine, and cisplatin; R-ESHAP = rituximab, etoposide, cytarabine, cisplatin, and methylprednisolone; R-GDP = rituximab, gemcitabine, dexamethasone, and cisplatin; R-GemOx = gemcitabine-oxaliplatin plus rituximab; R-ICE = rituximab, ifosfamide, carboplatin, and etoposide; R/R = relapsed and/or refractory; SCT = stem cell transplant; SD = standard deviation; trFL = transformed follicular lymphoma.

Provisional Funding Algorithm

Figure 1: Provisional Funding Algorithm Diagram for Large B-Cell Lymphoma



ASCT = autologous stem cell transplant; axi-cel = axicabtagene ciloleucel; BR = bendamustine and rituximab; CAR = chimeric antigen receptor; liso-cel = lisocabtagene maraleucel; pCPA = pan-Canadian Pharmaceutical alliance; R = rituximab; R-CHOP = rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone; tisa-cel = tisagenlecleucel.

^a Alternative R-chemotherapy regimens available.

^b If not received previously, polatuzumab-BR can be offered for bridging to CAR T-cell therapy.

^c Polatuzumab-BR is only funded for patients who are ineligible for ASCT and have received at least 1 prior therapy or have relapsed or progressed after prior ASCT. Polatuzumab-BR is only funded in patients who have not previously received polatuzumab-BR.

^d For patients who have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR T-cell therapy or have previously received CAR T-cell therapy.

^e For patients who have received 2 or more lines of systemic therapy and who have previously received or are unable to receive CAR T-cell therapy.

^f Epcoritamab received a time-limited recommendation in favour of reimbursement contingent on a future reassessment of additional evidence that addresses uncertainty.

^g Third-line options may be used in the fourth line, provided that therapy has not been used previously.

Description of the Provisional Funding Algorithm

First-line Therapy for All Patients

Currently, the first-line treatment for LBCL is R-CHOP chemotherapy, which consists of the combination of the following drugs:

- R for rituximab

- C for cyclophosphamide
- H for doxorubicin hydrochloride or hydroxydaunomycin
- O for vincristine sulphate (Oncovin)
- P for prednisone.

Subsequent-Line Therapies for Patients Who Are Transplant Eligible

Second-line treatment options for patients eligible for autologous stem cell transplant (ASCT) include axicabtagene ciloleucel and salvage chemotherapy regimens with or without rituximab followed by high-dose therapy and ASCT. Note that axicabtagene ciloleucel is under review for funding.

For patients who have received salvage chemotherapy and ASCT as second-line therapy, their third-line options are chimeric antigen receptor (CAR) T-cell therapies, polatuzumab vedotin with bendamustine and rituximab, glofitamab (for patients unable to receive or ineligible for CAR T-cell therapies), epcoritamab (for patients unable to receive or ineligible for CAR T-cell therapies), or a chemotherapy regimen with or without rituximab. Note that epcoritamab and glofitamab are under review for funding. CAR T-cell therapy options include axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. If the patient has not previously received polatuzumab vedotin with bendamustine, it can be offered for bridging to CAR T-cell therapies.

For patients who have received axicabtagene ciloleucel as a second-line option, their third-line options are:

- ASCT if they are transplant eligible, or
- polatuzumab vedotin with bendamustine and rituximab, glofitamab, epcoritamab, or a chemotherapy regimen with or without rituximab if they are not eligible for transplant.

Third-line options may be used in the fourth line of therapy provided the therapy has not been used previously.

Subsequent-Line Therapies for Patients Who Are Transplant Ineligible

Second-line treatment options for patients who are not eligible for ASCT include polatuzumab vedotin in combination with bendamustine and rituximab, and chemotherapy regimens with or without rituximab. Third-line treatments include CAR T-cell therapies or, if the patient is ineligible to receive or cannot receive CAR T-cell therapies, polatuzumab vedotin with bendamustine, glofitamab, epcoritamab, or a chemotherapy regimen with or without rituximab. Note that epcoritamab and glofitamab are under review for funding. CAR T-cell therapy options include axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. If the patient has not previously received polatuzumab vedotin with bendamustine, it can be offered for bridging to CAR T-cell therapies. Third-line options may be used in the fourth line of therapy provided the therapy has not been used previously.

Additional Remarks

Epcoritamab (Epkinly) received a time-limited recommendation in favour of reimbursement from pERC that is contingent on a future reassessment of additional evidence that addresses the uncertainty. pERC noted that Health Canada requires the sponsor to complete a phase III study and confirm that Epkinly improves the



survival in patients with DLBCL compared to bendamustine and rituximab (BR) or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Given that there is uncertainty in the magnitude of clinical benefit with Epkinly, reimbursement was recommended in a time-limited manner and contingent on a reassessment of the comparative efficacy and cost-effectiveness when the results of the phase III study are available from the sponsor.



Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.